InsiderTrades

Form 4 for FTH Faeth Therapeutics, Inc.

Accepted 2026-06-24 18:55:32 ET · period of report 2026-06-22 · accession 0002111813-26-000010 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-06-24 18:55 2026-06-22 FTH Parikh Anand Kiran Pres, CEO, Dir P - Purchase $19.76 +2,806 764.2K +0.4% +$55.4K
DM 2026-06-24 18:55 2026-06-22 FTH Parikh Anand Kiran Pres, CEO, Dir M - OptEx $1.16 +53.5K 817.7K +7% +$62.0K
DM 2026-06-24 18:55 2026-06-22 FTH Parikh Anand Kiran Pres, CEO, Dir M - OptEx $0.00 -53.5K 4,107 -93% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-06-22 P A 2,806 $19.76 764,234 D — —
2 Common Common Stock 2026-06-22 M A 45,252 $1.16 809,486 D — —
3 Common Common Stock 2026-06-22 M A 8,213 $1.16 817,699 D — —
4 Derivative Employee Stock Option (right to buy) 2026-06-22 M D 45,252 $0.00 91,632 D $1.16 · — to 2035-12-01 45,252 Common Stock (F1) Beginning on March 1, 2026, 12,258 shares vest monthly through January 1, 2027, with the balance fully vesting on February 1, 2027. (F2) The Form 4/A filed on June 16, 2026 (the "Form 4/A") contained a clerical error with respect to the expiration date of the reported security. This Form 4 corrects that clerical error to report the expiration date of the reported security as December 1, 2035. All other information reported on the Form 4/A remains unchanged.
5 Derivative Employee Stock Option (right to buy) 2026-06-22 M D 8,213 $0.00 4,107 D $1.16 · — to 2032-09-14 8,213 Common Stock (F3) Beginning August 1, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.